148,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Gebundenes Buch

Since the first edition of this book there has been great progress in the development of genetically engineered mouse (GEM) models of cancer. This revised and updated edition comprehensively describes the state-of-the-art in animal tumor model research.
Beverly A. Teicher and a panel of leading experts comprehensively describe the state-of-the-art in animal tumor model research. This volume updates and extends the comprehensive presentations in the first edition. The wide array of models detailed form the basis for the selection of compounds and treatments that go into clinical testing of…mehr

Produktbeschreibung
Since the first edition of this book there has been great progress in the development of genetically engineered mouse (GEM) models of cancer. This revised and updated edition comprehensively describes the state-of-the-art in animal tumor model research.
Beverly A. Teicher and a panel of leading experts comprehensively describe the state-of-the-art in animal tumor model research. This volume updates and extends the comprehensive presentations in the first edition. The wide array of models detailed form the basis for the selection of compounds and treatments that go into clinical testing of patients, and include syngeneic models, human tumor xenograft models, orthotopic models, metastatic models, and genetically engineered mouse models. Synthesizing many years experience with all the major in vivo models currently available for the study of malignant disease, Tumor Models in Cancer Research 2nd edition, provides preclinical and clinical cancer researchers alike with a comprehensive guide to the selection of these models, their effective use, and the optimal interpretation of their results.
Autorenporträt
Dr. Beverly A. Teicher is Senior Scientific Director in Cancer Research at Genzyme Molecular Oncology and Genzyme Corporation, Framingham, Massachusetts. She has authored or co-authored more than 400 scientific publications, has edited five books, senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.